Amid Sanofi’s multiyear effort to simplify its product portfolio, the drugmaker is offloading 11 central nervous system meds to life cycle management company Pharmanovia.
Sanofi is selling drugs that range the psycholeptic, anxiolytic, anti-epileptic and antipsychotic treatment fields. The drugs involved in the deal are Frisium, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren, Castilium, Gardenal, Tercian and Stemetil.
As for Pharmanovia, the company "revitalizes, extends and expands” the lifecycle of established medicine brands, it said in a statement.
The terms of the deal were not disclosed.
For years, Sanofi CEO Paul Hudson has been on a mission to center the company around first-in-class or best-in-class growth drivers.
It seems that many of Sanofi’s CNS meds have no place in the focused company, as the company inked a separate divestment of 15 CNS products to Neuraxpharm last year. That deal also included two pain and vascular treatments.
The company hasn't only sold of its CNS medicines. In July, Germany's Stada became the new owner of a clutch of former Sanofi consumer health products. That deal followed a similar 2021 sale of Sanofi consumer products.
Separately, Sanofi last summer returned exclusive worldwide rights to cancer med Libtayo to partner Regeneron for $900 million.
Meanwhile, Sanofi and Regeneron's superstar immunology drug Dupixent is on a roll. The companies recently presented phase 3 trial data proving the drug’s worth in chronic obstructive pulmonary disease, an indication the two will file for next year.
In the first half of the year, Dupixent pulled in nearly 4.9 billion euros, a 37% increase from the same period in 2022.
Now, Sanofi reached what Hudson calls a “new steady state," during which it will focus on new launches, including hemophilia A treatment Altuviiio and infant RSV antibody Beyfortus.